#USA #San Diego #Neurocrine Biosciences #VYKAT XR #Prader-Willi Syndrome

Soleno Therapeutics Showcases Breakthrough Data on VYKAT XR at ENDO 2026

At the recently concluded ENDO 2026 conference, Soleno Therapeutics, a subsidiary of Neurocrine Biosciences, presented groundbreaking data highlighting the effectiveness of its extended-release medication, VYKAT XR (diazoxide choline). The findings indicate that patients with Prader-Willi Syndrome (PWS) who resumed treatment after a brief interruption experienced sustained and significant improvements in hyperphagia and associated behavioral symptoms.

The data was derived from a meticulously designed Phase 3 clinical trial that included various stages, ensuring a robust collection of insights into the drug's long-term benefits. Specifically, the research showcased that just 13 weeks after patients resumed treatment following a 16-week randomized withdrawal period, improvements in hunger and behavioral symptom management were evident, continuing for up to two years.

Key Findings from the Study

Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, commented on the findings, stating, "These compelling data further reinforce our confidence in VYKAT XR as a safe and effective long-term treatment for hyperphagia in individuals four years of age and older living with Prader-Willi syndrome." Key outcomes from the study indicate:

• - Those who restarted VYKAT XR after a placebo period showed marked improvement within weeks, with a notable mean decrease of 4.5 points in hyperphagia scores after just 13 weeks.
• - Continuous treatment yielded sustained improvements, albeit slightly less pronounced compared to those who resumed after withdrawal, emphasizing the importance of uninterrupted therapy.
• - Remarkably, benefits were recorded across all six behavioral aspects associated with PWS after two years of continued treatment.

The implications of these findings are monumental, highlighting the potential for VYKAT XR to significantly enhance the quality of life for those affected by PWS, a rare genetic disorder characterized by excessive appetite and behavioral challenges.

Comparing VYKAT XR with Real-World Data

At ENDO 2026, another pivotal aspect discussed was a comparative analysis of VYKAT XR results against real-world data from the PATH for PWS Natural History Study. This analysis demonstrated statistically significant advantages for patients treated with VYKAT XR, confirming its efficacy over a typical course of care for PWS within a three-year time frame. The findings indicated:

• - First-year improvements in hyperphagia scores demonstrated treatment differences up to 6.2 points compared to controls.
• - Behavioral assessments revealed consistent advantages across all measured domains over the same three years, proving VYKAT XR's therapeutic robustness.

Understanding Prader-Willi Syndrome

PWS is an uncommon genetic disorder stemming from chromosomal abnormalities that lead to severe developmental challenges, predominantly hyperphagia. This constant need to eat can lead to serious health issues, including obesity and related comorbidities.

The challenges faced by individuals with PWS extend beyond physical health; emotional and psychological well-being are significantly impacted, leading to a dire need for effective treatment options.

The Role of VYKAT XR

VYKAT XR emerged as a beacon of hope for patients and their families. Approved by the U.S. FDA in March 2025, the drug is designated for managing hyperphagia in both pediatric and adult patients aged four and above. It has been designed specifically to improve not only hunger-related symptoms but also enhance broader behavioral responses in individuals living with PWS.

Given the data presented at ENDO 2026, the long-term outlook for patients using VYKAT XR appears promising. With safety being a priority, ongoing assessments regarding potential side effects, such as fluid retention and elevated glucose levels, are integral components of the drug's clinical oversight.

Conclusion

The recent findings at ENDO 2026 bring renewed optimism for individuals grappling with PWS and their families. With continued research and clinical trials, VYKAT XR stands to fundamentally alter the management landscape for this challenging condition, ultimately aiming to elevate the quality of life for many.

Important Safety Information

All medications come with risks; thus, thorough evaluations are advised before commencing treatment with VYKAT XR, particularly concerning contraindications, including known hypersensitivity to the medication.

In summary, VYKAT XR exemplifies how dedicated research and innovative therapies can converge to address the rigorous demands presented by rare disorders like Prader-Willi syndrome, paving pathways for hope and healing for affected individuals.